Nephrology
Clinical discussions on kidney disease management, dialysis, transplantation, and electrolyte disorders.
Recent Discussions
Would you refer an ESKD patient with an identified living donor for AV access placement if kidney transplantation is anticipated in 4 months?
Good question. I would not because it seems like it would only be a few months that the patient would be able to use the fistula, and I would spare them the surgery. One can make an argument, though, to place one as it may be needed if the transplant fails also. If there is a way one can move up the...
How would you manage an ESKD patient who complains of severe fatigue after hemodialysis, but does not experience intradialytic or post-dialysis hypotension and has not responded to dry weight adjustments?
Difficult but unfortunately not uncommon situation. My theory is that more frequent dialysis would be beneficial to avoid dramatic electrolyte and fluid shifts that occur with intermittent hemodialysis. Would see if peritoneal dialysis or home hemodialysis would be an option. If not, maybe 4 days pe...
Would you refer a patient for kidney only or kidney and liver transplantation if they develop advanced chronic kidney disease secondary to primary hyperoxaluria type 2?
Now that the data suggesting a benefit for nedosiran for PH2 is very disappointing, I think we have to say simultaneous liver and kidney. I have this one experience. My PH2 patient had kidney only because I was thinking that nedosiran would be effective. Ultimately, the kidney failed after about 5 y...
Do you prefer automated peritoneal dialysis during the day or night for a hospitalized patient with ESKD on PD?
I am very fortunate to have my home dialysis unit based in the hospital. Thus, our nurses are here and can set up/ take down the machine every day. We perform APD overnight, generally starting at around 5- 6 PM, before the last nurse leaves for the day, and concluding by 3- 4 AM, with the patient th...
How do you modify your peritonitis prevention strategy for a patient starting peritoneal dialysis who has a history of recurrent staphylococcal skin infections?
At the outset, let me state that I am unaware of any published data regarding this issue. Nor do I have personal experience to draw upon. So, what follows is what I THINK I would do if faced with this situation.First off, I would have a rather high threshold for starting PD in such a patient, especi...
Would you recommend adding a novel agent, such as lumasiran or nedosiran, to treat a newly diagnosed patient with primary hyperoxaluria type 1 who has preserved kidney function and persistent but significantly improved urinary oxalate levels following pyridoxine initiation?
I believe this is a fairly nuanced question. The answer really depends on the patient under question. Important considerations include how completely they responded to the pyridoxine, if there are any issues with them taking it regularly, and their current clinical course, including the number of st...
Would you recommend urinary glycolate testing prior to genetic testing in a patient with elevated urinary oxalate and suspicion for primary hyperoxaluria type 1?
Genetic testing today is much easier than urinary glycolate testing. Sending a saliva specimen is certainly more convenient than doing a 24-hour urine collection. At the moment, via pharma, the testing is free, so that is not a relevant variable either.
Which ESKD patients would you consider transitioning from hemodialysis to hemodiafiltration, given the FDA approval of a hemodiafiltration system in the US?
I believe once operational, we can transition all the patients in the dialysis unit equipped to perform it. In general, convention removes larger molecular weight substances, so patients who may derive the most benefit may be those who have, for example, dialysis-associated amyloidosis/carpal tunnel...
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
For patients with heart failure with reduced ejection fraction (HFrEF) and co-existing end-stage renal disease (ESRD), the use of sodium-glucose co-transporter-2 inhibitors SGLT2i and angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor ARB/ARNI therapies requires careful considera...
What is your approach to systemic anticoagulation for patients with hypoalbuminemia and nephrotic syndrome secondary to a non-membranous nephropathy condition?
Patients with nephrotic syndrome (NS) and hypoalbuminemia have a several-fold higher risk of venous thromboembolism (VTE) than the general population and also a somewhat higher risk of arterial thromboembolism (ATE), such as MI and stroke. This risk seems to be higher in membranous nephropathy (MN) ...